{
  "content": "Rate control in atrial fibrillation\nLancet. 2016; 388:818-828\nFull Text\nFull Text (PDF)\nScopus (134)\nPubMed\nGoogle Scholar\nBeta-blockers are most frequently used as rate-controlling agents due to their rapid onset of action, dose-dependent effect and safety profile.7\n7.\nScheuermeyer, F.X. ∙ Grafstein, E. ∙ Stenstrom, R. ∙ et al.\nSafety and efficiency of calcium channel blockers versus beta-blockers for rate control in patients with atrial fibrillation and no acute underlying medical illness\nAcad Emerg Med. 2013; 20:222-230\nCrossref\nScopus (42)\nPubMed\nGoogle Scholar\nBeta-blockers are also beneficial in patients with HFrEF,56\n56.\nMcDonagh, T.A. ∙ Metra, M. ∙ Adamo, M. ∙ et al.\n2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure",
  "source": "https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00220-X/fulltext",
  "chunk_id": "fb68f306-c2ab-4c81-8641-9d1c8aad3098",
  "similarity_score": 0.3940590023994446,
  "query": "amiodarone versus beta-blockers atrial fibrillation randomized controlled trial effectiveness rhythm control rate control",
  "rank": 40,
  "title": "Atrial fibrillation: better symptom control with rate and rhythm management",
  "authors": "Dhiraj Gupta, Michiel Rienstra, Isabelle C. van Gelder, Laurent Fauchier",
  "year": "2024",
  "journal": "The Lancet Regional Health – Europe",
  "reference": "Gupta, D., Rienstra, M., van Gelder, I. C., & Fauchier, L. (2024). Atrial fibrillation: better symptom control with rate and rhythm management. The Lancet Regional Health – Europe, 37100801. https://doi.org/10.1016/j.lanepe.2023.100801",
  "doi": "10.1016/j.lanepe.2023.100801",
  "chunk_index": 89,
  "total_chunks": 154,
  "retrieved_at": "2025-07-24T21:57:43.521912"
}